MediWound to Present at the 45th Annual TD Cowen Health Care Conference

Rhea-AI Summary

MediWound (Nasdaq: MDWD), a specialist in enzymatic therapeutics for tissue repair, has announced its participation in the 45th Annual TD Cowen Health Care Conference in Boston. CEO Ofer Gonen will deliver a corporate overview on March 5, 2025, at 11:50 AM ET.

The presentation will be accessible through a live webcast, with registration available online. A replay will be made available on MediWound's website in the Events & Presentations section of the Investors area. The management team will also conduct one-on-one meetings with investors during the conference, which can be arranged through TD Cowen representatives.

News Market Reaction – MDWD

+1.81%

1 alert

+1.81% News Effect

On the day this news was published, MDWD gained 1.81%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will present a corporate overview at the upcoming 45th Annual TD Cowen Health Care Conference, taking place in Boston, MA on Wednesday, March 5, 2025, at 11:50 AM ET. To listen to the live webcast of the presentation, please register here.

A replay of the event will also be posted to MediWound’s website on the Events & Presentations page of the Investors section.

In addition, the MediWound management team will host one-on-one meetings during the conference. Interested investors are encouraged to contact their TD Cowen representative to schedule a meeting.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.

MediWound’s first drug, NexoBrid^®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx^®, a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx has distinct advantages over the currently available $375+ million drug for wound debridement, presenting a unique opportunity for significant market growth.

For more information visit www.mediwound.com and follow us on LinkedIn.

MediWound Contacts:
Hani Luxenburg	Daniel Ferry
Chief Financial Officer	Managing Director
MediWound Ltd.	LifeSci Advisors, LLC
ir@mediwound.com	daniel@lifesciadvisors.com

Media Contact:

Ellie Hanson

FINN Partners for MediWound

ellie.hanson@finnpartners.com +1-929-588-2008

FAQ

When is MediWound (MDWD) presenting at the TD Cowen Health Care Conference 2025?

MediWound is scheduled to present on Wednesday, March 5, 2025, at 11:50 AM ET in Boston, MA.

How can investors watch MediWound's (MDWD) presentation at the TD Cowen conference?

Investors can watch the presentation through a live webcast by registering online, and a replay will be available on MediWound's website in the Events & Presentations section.

Can investors meet with MediWound (MDWD) management at the TD Cowen conference?

Yes, investors can schedule one-on-one meetings with the MediWound management team by contacting their TD Cowen representative.

Who will be presenting for MediWound (MDWD) at the 2025 TD Cowen Health Care Conference?

Chief Executive Officer Ofer Gonen will present the corporate overview at the conference.